https://www.astrazeneca.com/media-centre/press-releases/2026/us-fda-decision-date-camizestrant-extended.html
US FDA decision date extended for SERENA-6 filing of camizestrant to enable review of additional...
us fdadecisiondateextendedserena
https://studienfinder.mamazone.de/studien/cambria-2
CAMBRIA-2 – Adjuvante Therapie mit Camizestrant | mamazone Studienfinder
CAMBRIA-2 prüft adjuvante Therapie mit Camizestrant bei Hormonrezeptor-positivem, HER2-negativem Brustkrebs im frühen Stadium mit erhöhtem.
cambriaadjuvantetherapiemitcamizestrant
https://kolpulse.com/kol-pulse-trial-profile-serena4
SERENA-4 Trial: Camizestrant Misses 1L PFS in ER+ Breast Cancer
SERENA-4 (NCT04711252): camizestrant + palbociclib missed the primary PFS endpoint in 1L ER+/HER2- advanced breast cancer (N=1,371; numerical improvement...
breast cancerserenatrialcamizestrantmisses